The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Is the current dose of pembrolizumab approved for treating lung cancer too high?
Daniel Goldstein, MD, from Davidoff Cancer Center, Petah Tikva, Israel, talks to us about the possibility of lowering the current FDA-approved dose of pembrolizumab for the treatment of PD-L1-positive lung cancer and notes that studies have shown equivalent efficacies of the drug in two different doses. He states that lowering the prescription dose from 200mg, the FDA-approved dose, to 150mg, may save $0.8 billion annually, whilst maintaining the same level of efficacy in patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
